Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | CCKBR | P32239 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.35 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2921270 | 1.00 | GAA (0.38) | GAASMN1; SMN2HTR7DRD2CCKBR | |
| SCHEMBL12888485 | 0.90 | PABPC1 (0.39) | SMN1; SMN2DRD2PTGS1CYP3A4CYP2C9 | |
| SCHEMBL1239775 | 0.90 | PABPC1 (0.39) | SMN1; SMN2DRD2PTGS1CYP3A4CYP2C9 | |
| SCHEMBL1237123 | 0.90 | PABPC1 (0.39) | SMN1; SMN2DRD2PTGS1CYP3A4CYP2C9 | |
| SCHEMBL1238384 | 0.90 | PABPC1 (0.39) | SMN1; SMN2DRD2PTGS1CYP3A4CYP2C9 | |
| SCHEMBL12888392 | 0.90 | SMN1; SMN2 (0.40) | GAASMN1; SMN2DRD2CCKBRPTGS1 | |
| SCHEMBL12888484 | 0.86 | SMN1; SMN2 (0.40) | GAASMN1; SMN2HTR7DRD2 | |
| SCHEMBL12888440 | 0.86 | SMN1; SMN2 (0.40) | GAASMN1; SMN2HTR7DRD2 | |
| SCHEMBL1236963 | 0.86 | SMN1; SMN2 (0.40) | GAASMN1; SMN2HTR7DRD2 | |
| SCHEMBL12888487 | 0.86 | SMN1; SMN2 (0.40) | GAASMN1; SMN2HTR7DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1726587-B1 | BENZOTHIAZIN-3-ONE COMPOUND AND INTERMEDIATE THEREFOR | DAINIPPON SUMITOMO PHARMA CO (JP) | 2010-09-01 | — | — | EP | disclosed |
| US-20100009976-A1 | BENZOTHIAZIN-3-ONE COMPOUND AND INTERMEDIATE THEREFOR | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-7598240-B2 | Benzothiazin-3-one compound and intermediate therefor | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-10-06 | — | — | US | disclosed |
| US-20080058321-A1 | BENZOTHIAZIN-3-ONE COMPOUND AND INTERMEDIATE THEREFOR | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-03-06 | — | — | US | disclosed |
| EP-1726587-A1 | BENZOTHIAZIN-3-ONE COMPOUND AND INTERMEDIATE THEREFOR | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009976-A1 | BENZOTHIAZIN-3-ONE COMPOUND AND INTERMEDIATE THEREFOR | HDAC11, HDAC8, MMP11 | GAA 804/4885SMN1; SMN2 4702/4885HTR7 2307/4885 |
| US-20080058321-A1 | BENZOTHIAZIN-3-ONE COMPOUND AND INTERMEDIATE THEREFOR | HDAC11, HDAC8, MMP11 | GAA 804/4885SMN1; SMN2 4702/4885HTR7 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.